{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T12:24:05Z","timestamp":1784809445479,"version":"3.55.0"},"reference-count":59,"publisher":"Media Sphere Publishing House","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2025,10,6]]},"abstract":"<jats:p>Objective. To study the antidepressant efficacy and the tolerability of agomelatine (Valdoxan) in daily clinical practice in patients with a depressive episode that occurred after COVID-19. Material and methods. The final analysis included 103 patients (70.9% women, average age 45 years). Of these, 78.6% have had mild COVID-19 in the last 3 months, and 21.4% have had moderate COVID-19. The average time from the onset of infection to inclusion in the study was 2.1\u00b10.7 months. At the start of the study, 53.4% of patients had a mild depressive episode, and 46.6% had a moderate depressive episode. Clinical and psychopathological, psychometric (HAMD-17, CGI, SF-36), and statistical methods of investigation were used. Results. A significant decrease in the severity of depression was revealed. The average overall score on the HAMD-17 scale decreased compared to baseline by 2.6\u00b13.3, 6.7\u00b15.3, and 10.9\u00b14.9 at weeks 2, 4, and 8 of agomelatin administration, respectively (p&lt;0.0001). Mental and physical indicators on the SF-36 scale also significantly improved compared to baseline (p&lt;0.0001). By the end of the study, 81.4% of patients had responded to therapy, 71.6% had achieved remission according to the criteria established in the study. It was found that the initial value of the total HAMD-17 score has a statistically significant effect (p&lt;0.0001) on the outcome of depression therapy after COVID-19, an additional contribution is made by the prescription of COVID-19 disease. Agomelatin was well tolerated during the 8 weeks of follow-up. Conclusion. The results indicate a high antidepressant and anxiolytic effectiveness and safety of agomelatine after 8 week of treatment of patients with depression after COVID-19 infection. The results of the study add to the knowledge about the antidepressant effectiveness of agomelatine and suggest that it may become a drug for the treatment of MDE in patients who have suffered COVID-19 infection.<\/jats:p>","DOI":"10.17116\/jnevro202512509190","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:37:56Z","timestamp":1759765076000},"page":"90","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness and tolerability of agomelatine (Valdoxan) in the treatment of depression after COVID-19 (TELESFOR study)"],"prefix":"10.17116","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8653-596X","authenticated-orcid":false,"given":"V.E.","family":"Medvedev","sequence":"first","affiliation":[{"name":"Peoples\u2019 Friendship University of Russia named after Patrice Lumumba","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6327-3546","authenticated-orcid":false,"given":"A.N.","family":"Bogolepova","sequence":"additional","affiliation":[{"name":"Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency","place":["Moscow, Russia"]},{"name":"Pirogov Russian National Research Medical University","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202512509190-1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12839"},{"key":"key-10.17116\/jnevro202512509190-2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0968-3"},{"key":"key-10.17116\/jnevro202512509190-3","doi-asserted-by":"publisher","DOI":"10.1080\/13651501.2021.1993924"},{"key":"key-10.17116\/jnevro202512509190-4","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212205223"},{"key":"key-10.17116\/jnevro202512509190-5","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2021-2-111-116"},{"key":"key-10.17116\/jnevro202512509190-6","doi-asserted-by":"publisher","DOI":"10.51793\/OS.2021.15.98.005"},{"key":"key-10.17116\/jnevro202512509190-7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2021.07.018"},{"key":"key-10.17116\/jnevro202512509190-8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00810-3"},{"key":"key-10.17116\/jnevro202512509190-9","unstructured":"Avedisova AS, Zakharova KV, Marachev MP. Results of the JAZZ observational program: \u00abThe effectiveness of the drug agomelatine (Valdoxan) in the treatment of patients with anxiety depression in the framework of major depressive disorder. Psychiatry and psychopharmacotherapy. 2013;6:14-22. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-10","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2018118111109"},{"key":"key-10.17116\/jnevro202512509190-11","doi-asserted-by":"crossref","unstructured":"Medvedev VE. Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disorders: results of the National Multicenter Observational Study PULSE. Neuropsychiatric disease and treatment. 2017;13:1141-1151","DOI":"10.2147\/NDT.S129793"},{"key":"key-10.17116\/jnevro202512509190-12","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2019-1-131-140"},{"key":"key-10.17116\/jnevro202512509190-13","unstructured":"Volel BA. Safety and efficacy of Valdoxan for the treatment of anxiety and depressive disorders in clinical practice (based on the results of the OCTAVE protocol). Psychiatry and psychopharmacotherapy. 2015;17(2):9-14. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-14","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(20)30203-0"},{"key":"key-10.17116\/jnevro202512509190-15","doi-asserted-by":"crossref","unstructured":"Renaud-Charest O, Lui L, Eskander S, et al. Onset and frequency of depression in post-COVID-19 syndrome: a systematic review. J Psychiatr Res. 2021;144:129-137","DOI":"10.1016\/j.jpsychires.2021.09.054"},{"key":"key-10.17116\/jnevro202512509190-16","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2020-6-4-10"},{"key":"key-10.17116\/jnevro202512509190-17","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2021121052122"},{"key":"key-10.17116\/jnevro202512509190-18","doi-asserted-by":"publisher","DOI":"10.32000\/2072-1757-2021-1-29-33"},{"key":"key-10.17116\/jnevro202512509190-19","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2020.102196"},{"key":"key-10.17116\/jnevro202512509190-20","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2022-5-36-42"},{"key":"key-10.17116\/jnevro202512509190-21","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2021121041152"},{"key":"key-10.17116\/jnevro202512509190-22","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2021-2-111-116"},{"key":"key-10.17116\/jnevro202512509190-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2021.03.010"},{"key":"key-10.17116\/jnevro202512509190-24","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01021-4"},{"key":"key-10.17116\/jnevro202512509190-25","doi-asserted-by":"publisher","DOI":"10.3390\/life11101056"},{"key":"key-10.17116\/jnevro202512509190-26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.22760"},{"key":"key-10.17116\/jnevro202512509190-27","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2022.12.001"},{"key":"key-10.17116\/jnevro202512509190-28","unstructured":"Dobrodeeva V, Abdyrahmanova A, Astafeva D, et al. Pharmacogenetic aspects of COVID-19 management and post-COVID-19 depression treatment with fluvoxamine. Psychiatr Danub. 2022;34(Suppl 8):25-30"},{"key":"key-10.17116\/jnevro202512509190-29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2021.09.009"},{"key":"key-10.17116\/jnevro202512509190-30","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2023.02.006"},{"key":"key-10.17116\/jnevro202512509190-31","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro201611611126-34"},{"key":"key-10.17116\/jnevro202512509190-32","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145707007766"},{"key":"key-10.17116\/jnevro202512509190-33","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05347blu"},{"key":"key-10.17116\/jnevro202512509190-34","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v68n1112"},{"key":"key-10.17116\/jnevro202512509190-35","doi-asserted-by":"crossref","unstructured":"Quera-Salva MA, Hajak G, Philip P, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. Int Clin Psychopharmacol. 2011;26(5):252-262","DOI":"10.1097\/YIC.0b013e328349b117"},{"key":"key-10.17116\/jnevro202512509190-36","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2024-6-61-70"},{"key":"key-10.17116\/jnevro202512509190-37","doi-asserted-by":"crossref","unstructured":"Medvedev VE, Ter-Israelyan AYu, Frolova VI, et al. The experience of using valdoxan in depression with cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;2:77-80. (In Russ.)","DOI":"10.17116\/jnevro20181182177-80"},{"key":"key-10.17116\/jnevro202512509190-38","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro2018118111109"},{"key":"key-10.17116\/jnevro202512509190-39","unstructured":"Medvedev VE, Frolova VI, Ter-Israelyan AYu, et al. Therapy of depressive disorders with circadian rhythms. Psychiatry and psychopharmacotherapy. 2018;20(5):38-43. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-40","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3140"},{"key":"key-10.17116\/jnevro202512509190-41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1888"},{"key":"key-10.17116\/jnevro202512509190-42","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"key-10.17116\/jnevro202512509190-43","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852913000060"},{"key":"key-10.17116\/jnevro202512509190-44","doi-asserted-by":"publisher","DOI":"10.2165\/11534420-000000000-00000"},{"key":"key-10.17116\/jnevro202512509190-45","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.09.006"},{"key":"key-10.17116\/jnevro202512509190-46","unstructured":"Ivanov SV. Valdoxan (agomelatine) in the treatment of moderate and severe depression of non-psychotic level in outpatient and hospital practice (results of the Russian multicenter study \u00abCHRONOS\u00bb). Psychiatry and psychopharmacotherapy. 2009;6:14-17. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-47","unstructured":"Smulevich AB, Andryushchenko AV, Beskova DA. Therapy of non-psychotic depression with the antidepressant agomelatine (Valdoxan): the results of the observational multicenter study \u00abRHYTHM\u00bb. Psychiatry and psychopharmacotherapy. 2010;12(4):4-11. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-48","unstructured":"Vorobyeva OV. Valdoxane in the treatment of depression in neurological practice: results of the Russian multicenter naturalistic study \u00abResonance\u00bb. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(9):47-51. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-49","unstructured":"Tsygankov BD, Yaltonskaya AV, Filippskikh SV. Valdoxan (Agomelatine) in the treatment of severe and moderate nonpsychotic depression (results of an observational study). Review of Psychiatry and Medical Psychology. Bekhtereva. 2011;1:37-40. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-50","unstructured":"Yakhno NN. Voznesenskaya T.G. Efficacy and tolerability of agomelatine (Valdoxan) in the treatment of mild and moderate depressive disorders in neurological practice (results of the Russian multicenter study \u00abKamerton\u00bb). Neurological journal. 2012;17(1):43-49. (In Russ.)"},{"key":"key-10.17116\/jnevro202512509190-51","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221105128"},{"key":"key-10.17116\/jnevro202512509190-52","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.963"},{"key":"key-10.17116\/jnevro202512509190-53","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2013.03.008"},{"key":"key-10.17116\/jnevro202512509190-54","doi-asserted-by":"publisher","DOI":"10.1016\/j.archoralbio.2017.05.015"},{"key":"key-10.17116\/jnevro202512509190-55","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.04.001"},{"key":"key-10.17116\/jnevro202512509190-56","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11144038"},{"key":"key-10.17116\/jnevro202512509190-57","doi-asserted-by":"publisher","DOI":"10.30906\/0869-2092-2021-84-2-104-112"},{"key":"key-10.17116\/jnevro202512509190-58","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1052710"},{"key":"key-10.17116\/jnevro202512509190-59","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.892"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T15:38:15Z","timestamp":1759765095000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova\/2025\/9\/1199772982025091090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":59,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,10,6]]}},"alternative-id":["10.17116\/jnevro202512509190"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202512509190","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,6]]}}}